Working... Menu
Trial record 35 of 580 for:    Recruiting, Not yet recruiting, Available Studies | Superior

Upper-limb Active Function and Botulinum Toxin A (ULAFBoT-Stroke)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03783572
Recruitment Status : Not yet recruiting
First Posted : December 21, 2018
Last Update Posted : December 21, 2018
Information provided by (Responsible Party):
University Hospital, Toulouse

Brief Summary:
This study in an observational, prospective and longitudinal study. The aim of the study is to evaluate the effect of botulinum toxin type A (BTX) injections into the elbow flexors on the reduction of spastic co-contractions (spastic co-contraction index, SCCI) during an active elbow extension in chronic post-stroke patients.TBA injections are performed as part of routine care

Condition or disease Intervention/treatment Phase
Stroke Muscle Spasticity Upper Extremity Paralysis Other: Clinical evaluation Other: Clinical evaluation and Instrumental evaluation Not Applicable

Detailed Description:

BTX is a valuable treatment in the management of the focal muscle overactivity (spasticity) following acquired brain injury. If BTX injections reduce spasticity, few studies have examined its effect on the improvement of active function of the upper limb.

Motor task involves the muscles agonists and antagonists by phenomena of muscular coactivation.

In post-stroke patients, functional cortical reorganization secondary to the phenomena of plasticity leads to a reduced motor selectivity. The increase of muscular coactivation correspond to the spastic cocontraction, which are a little evaluated in clinical practice and research, whereas they appear to have a greater impact than spasticity on limitation of active movement.

This study does not evaluate the efficacy of treatment (BTX injection) but the effect of this treatment on a component of muscle hyperactivity, the spastic cocontraction.

In addition to the 5 follow-up visits, patients have 6 intercurrent visits. These visits are less invasive and include only a clinical assessment with surface EMG registration. These evaluations will evaluate the efficacy and harm effect of BTX on clinical parameters and on the spastic co-contraction index. Five intercurrent visits I1, I2, I3, I4, I5 are perform respectively 2 weeks after T1 and, 3, 6, 9, 12 weeks after T2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 2 groups, one with 40 stroke patients and the control group with 40 healthy subjects prospective, longitudinal, without blinding, multicenter.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Upper-limb Active Function and Botulinum Toxin A
Estimated Study Start Date : January 2019
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox

Arm Intervention/treatment
Experimental: Stroke patients
40 stroke patients : Injection of the TBA and the investigator will compare the measure of spastic cocontraction index (ICCS) during different movement before versus 4 weeks after injection of TBA : Clinical evaluation and Instrumental evaluation TBA injections are performed as part of routine care
Other: Clinical evaluation and Instrumental evaluation
For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.

Active Comparator: Control Group
The control group : Clinical evaluation consists in the search for criteria of non-inclusion and manual laterality score The will ha an Instrumental review just like the patient : concomitant evaluation of the 3D kinematics of the dominant upper limb, EMG of the triceps brachii muscles, biceps brachii, brachio-radial, brachial; associated with EEG recording, during active extension and elbow flexion movements, of the dominant upper extremity, at spontaneous and maximal speed Clinical evaluation
Other: Clinical evaluation
For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score

Primary Outcome Measures :
  1. Measurement of the spastic co-contraction index (SCCI) [ Time Frame: 4 weeks ]
    Measurement of the spastic co-contraction index (SCCI) during a maximal active elbow extension, obtained from the EMG signal of the elbow muscles on the paretic side before / after BTX injection.

Secondary Outcome Measures :
  1. Spasticity of the elbow flexors [ Time Frame: 4 weeks ]
    Spasticity of the elbow flexors according to Tardieu scale at different time : Spasticity is muscle resistance during fast-moving passive stretching. It is evaluated by the Tardieu scale and it consists in studying the evolution of the muscular reaction and its angle of occurrence.The muscular reaction to the rapid stretching of the muscle is graded in 5 classes from 0 to 4

  2. Limitation of the active movement angle 5LAMA) for elbow extension [ Time Frame: 4 weeks ]
    Limitation of the active movement angle for elbow extension at different time : the subtractionof the angle of maximum elbow extension obtained during passive stretching of muscles at the maximum elbow extension angle obtained during a voluntary active contraction. As part of the protocol, the LAMA will be instrumentally measured with the 3D kinematic system.

  3. The Fugl-Meyer Motor Function Assessment [ Time Frame: 4 weeks ]
    Fugl-Meyer score at different visits : The Fugl-Meyer Motor Function Assessment, is a scale of evaluation of the reference voluntary motricity in the cerebral adult. The FMA-Motor portion of the upper limb is rated 66. It has high validity, reliability and sensitivity to change.

  4. Functional capabilities with Wolf Motor Function Test (WMFT) score at different visits [ Time Frame: 4 weeks ]
    Functional capabilities with WMFT score : standardized scale assessing upper limb capacities in cerebral palsy adults The scale consists of 17 standardized tests, sorted in order of increasing complexity, which solicit the proximal joints through analytical movements, and progress towards the distal joints through the execution of functional tasks of grasping, grasping and manipulating objects, evaluating single- and bimanual grips. The handover device is standardized. WMFT assesses three aspects of movement

  5. EEG quantification of bilateral cortical activity during movement [ Time Frame: 4 weeks ]
    EEG quantification of bilateral cortical activity during movement to calculate the Desynchronization index (ERD) identifying hyperactivity in the ipsilesional cortex

  6. Cortico-spinal excitability of the motor cortex [ Time Frame: 4 weeks ]
    Cortico-spinal excitability of the motor cortex assessed with TMS : TMS is a non-invasive magnetic stimulation technique that evaluates the integrity of the corticospinal tract. One of the measures used in current practice is that of the amplitude variations of a EMF collected by EMG of the surface elbow flexors as a function of stimulation intensity. The intensity curve is an index of cortical excitability.

  7. Integrity of encephalic motor tracts [ Time Frame: 4 weeks ]

    Integrity of encephalic motor tracts with an anatomic and diffusion RMI : An encephalic MRI without injection of contrast material with an anatomical sequence and a diffusion sequence will make it possible to evaluate the integrity of the motor pathways at the cortical level, the internal capsule, and the brainstem.

    The interest will be to evaluate the level of integrity of the cortico-spinal tract compared to other bundles, with the hypothesis that a lesion of the cortico-spinal tract favors the in play of the accessory motorways

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Stroke group :

Inclusion Criteria:

  • Cortical and/or subcortical ischemic or haemorrhagic stroke for at least 6 months;
  • Indication to an injection of BTA in the elbow flexor muscles according to the usual clinical criteria: request of elbow extension improvement with a functional or aesthetic objective;
  • Being under prescription of abobotulinum toxin A (DYSPORT®, Ipsen-Pharma);
  • Ability of active elbow extension> 20 degrees;
  • Limitation of active movement of elbow extension > 15 degrees or decreased or 50% decrease in the active elbow extension rate;
  • Patients who have never been treated with BTX or only a first injection that having targeted the elbow flexors more than 4 months ago;
  • Age> 18 years;
  • Signature of informed consent;
  • Subject affiliated to the social security coverture.

Exclusion Criteria:

  • Passive limitation of elbow extension > 30 degrees;
  • Pain during active movements of elbow flexion/extension;
  • Cognitive disorder with limited comprehension of three basic instructions (like the test of the 3 papers of the MMS);
  • Evolutionary or decompensated neurological disease;
  • Unstabilized epilepsy;
  • Anticoagulant treatment with a curative dose or hemostasis disorder that contraindicates intramuscular injections;
  • Claustrophobia or metallic foreign bodies contraindicated for MRI;
  • General contraindication for botulinum toxin injection: hypersensitivity to the active substance or to one of the excipients, swallowing disorder, chronic respiratory disorders, antecedent of myasthenia or Lambert Eaton syndrome; antecedent of neuromuscular disease; surgery with curarization for less than a month; current treatment with aminoglycoside, aminoquinoline, cyclosporine or anticholinesterase.
  • Presence of skin infection or inflammation at the injection site.
  • Legal incapacity.
  • Pregnant or breastfeeding woman;
  • Woman with a desire to become pregnant within 18 months.
  • Non-menopausal woman (a postmenopausal state is defined as no menses for 12 months without an alternative medical cause) who does not use one of the following contraceptive methods considered highly effective : intrauterine device, oestroprogestonic contraception or progestogen hormonal contraception associated with inhibition of ovulation, intrauterine hormone-releasing system, or bilateral tubal occlusion.

Control group

  • inclusion criteria:

    • Age> 18 years
    • Signature of informed consent.
  • exclusion criteria:

    • History of orthopedic or neurologic disorders;
    • Subject expert in a sport intensively requiring the upper limbs (at least departmental competition level);
    • Legal incapacity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03783572

Layout table for location contacts
Contact: David Gasq, MD 05 61 32 28 42 ext 33
Contact: Audrey Tomasik 05 61 77 85 97 ext 33

Layout table for location information
University Hospital Toulouse Not yet recruiting
Toulouse, France, 31059
Contact: David Gasq, MD    05 61 32 28 42 ext 33   
Contact: Audrey TOMASIK    05 61 77 85 97 ext 33   
Sponsors and Collaborators
University Hospital, Toulouse
Layout table for investigator information
Principal Investigator: David Gasq, MD University Hospital, Toulouse

Layout table for additonal information
Responsible Party: University Hospital, Toulouse Identifier: NCT03783572     History of Changes
Other Study ID Numbers: RC31/17/0455
2018-000941-38 ( EudraCT Number )
First Posted: December 21, 2018    Key Record Dates
Last Update Posted: December 21, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital, Toulouse:
Botulinum toxin
Cerebrovascular Accident
upper-limb movement
spastic cocontraction

Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Spasticity
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Botulinum Toxins
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents